Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perovskia abrotanoides extract versus Glucantime for cutaneous leishmaniasis
IRCT20150721023282N19Phase 3Completed
- Sponsor
- Isfahan University of Medical Sciences
- Start
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of meglumine antimoniate in cutaneous leishmaniasis (CL) (2 arms), sponsored by Isfahan University of Medical Sciences. Primary endpoint: Clinical response. Started Sep 2021; status: completed.
02
Drugs
meglumine antimoniate
03
Conditions
cutaneous leishmaniasis (CL)
Beyond the preview
Go deeper on IRCT20150721023282N19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20150721023282N19.